Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Published: 01 January 1970

Recent Videos: ASCO GU Conference Coverage

video

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers opinion on when sipuleucel-T should be used in the treatment ...

video

Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, offers opinion on whether patients in the first line setting should ...

video

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on combining checkpoint inhibitors with PARP inhibitors, chemotherapy, and anti-hormone ...

video

Michael Atkins, MD, regarding single agent TKIs in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers combination pembrolizumab and olaparib and what primary endpoints should look ...

video

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination ...

video

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, tell us about the results of KEYNOTE 365 investigating the use ...

video

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on how androgen deprivation therapy (ADT) is changing for men ...

video

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer ...

Related Videos

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

video-image

Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI

video-image

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

video-image

Michael Atkins, MD, regarding single agent TKIs in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

video-image

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

video-image

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

video-image

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPC

video-image

Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019

video-image

Evan Yu, MD, considers when sipuleucel-T should be used in treatment of mCRPC

video-image

Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC

video-image

Evan Yu, MD, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, discusses combining checkpoint inhibitors in mCRPC

video-image

Evan Yu, MD, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Sumit K. Subudhi, MD, PhD, on when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC

video-image

Bridget F. Koontz, MD, speculates on the evolving landscape of prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, considers the outcomes of the KEYNOTE 365 study

video-image

Bridget F. Koontz, MD, regarding new guidelines on hypofractionated EBRT in prostate cancer

video-image

Tomasz Beer, MD, regarding the ARAMIS study in nmCRPC from GU 2019

video-image

Bridget F. Koontz, MD, on moderate hypofractionation & ultra-hypofractionation in prostate cancer

video-image

Tomasz Beer, MD, elaborates on recent data utilizing LuPSMA in men with mCRPC

video-image

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

video-image

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

video-image

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

video-image

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

video-image

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

video-image

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

video-image

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

video-image

Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019

video-image

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

video-image

Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC

video-image

Yair Lotan, MD, considers the role of checkpoint inhibitors in bladder cancer

video-image

Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer

video-image

Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019

video-image

Yair Lotan, MD, on the challenges using biomarkers for treatment selection in bladder cancer

video-image

Mark T. Fleming, MD, regarding the Aramis study in prostate cancer

video-image

Yair Lotan, MD, on molecular characterization & subtyping data in bladder cancer

video-image

Mark T. Fleming, MD, offers his impression of the LATITUDE study in NDx-HR mCNPC

video-image

Yair Lotan, MD, considers the latest in screening for high-risk asymptomatic bladder cancer

video-image

Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer

video-image

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

video-image

Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer

video-image

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

video-image

Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma

video-image

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC